Quinoxalinedione, the Glossary

Table of Contents

1. 16 relations: AMPA receptor, Becampanel, Caroverine, CNQX, DNQX, Drug, Fanapanel, Ionotropic glutamate receptor, Kainate receptor, Licostinel, NBQX, NMDA receptor, O-Phenylenediamine, Receptor antagonist, Selurampanel, Zonampanel.

2. Quinones
3. Quinoxalines

AMPA receptor

The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (also known as AMPA receptor, AMPAR, or quisqualate receptor) is an ionotropic transmembrane receptor for glutamate (iGluR) and predominantly Na+ ion channel that mediates fast synaptic transmission in the central nervous system (CNS).

See Quinoxalinedione and AMPA receptor

Becampanel

Becampanel (INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC50. Quinoxalinedione and Becampanel are Lactams and quinoxalines.

See Quinoxalinedione and Becampanel

Caroverine

Caroverine (Spasmium, Tinnitin, Tinnex) is a muscle-relaxing drug used in Austria and Switzerland to relieve spasms in smooth muscles (which include intestines, arteries, and other organs), and the use in those countries was extended to aid with cerebrovascular diseases there, and eventually to treat tinnitus. Quinoxalinedione and Caroverine are Lactams and quinoxalines.

See Quinoxalinedione and Caroverine

CNQX

CNQX or cyanquixaline (6-cyano-7-nitroquinoxaline-2,3-dione) is a competitive AMPA/kainate receptor antagonist. Quinoxalinedione and CNQX are Lactams and quinoxalines.

See Quinoxalinedione and CNQX

DNQX

DNQX (6,7-dinitroquinoxaline-2,3-dione) is a competitive antagonist at AMPA and kainate receptors, two ionotropic glutamate receptor (iGluR) subfamilies. Quinoxalinedione and DNQX are Lactams, Quinones and quinoxalines.

See Quinoxalinedione and DNQX

Drug

A drug is any chemical substance other than a nutrient or an essential dietary ingredient, which, when administered to a living organism, produces a biological effect.

See Quinoxalinedione and Drug

Fanapanel

Fanapanel (INN, code name ZK-200775), also known as MPQX, is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor. Quinoxalinedione and Fanapanel are quinoxalines.

See Quinoxalinedione and Fanapanel

Ionotropic glutamate receptor

Ionotropic glutamate receptors (iGluRs) are ligand-gated ion channels that are activated by the neurotransmitter glutamate.

See Quinoxalinedione and Ionotropic glutamate receptor

Kainate receptor

Kainate receptors, or kainic acid receptors (KARs), are ionotropic receptors that respond to the neurotransmitter glutamate.

See Quinoxalinedione and Kainate receptor

Licostinel

Licostinel (INN) (code name ACEA-1021) is a competitive, silent antagonist of the glycine site of the NMDA receptor (Kb. Quinoxalinedione and Licostinel are quinoxalines.

See Quinoxalinedione and Licostinel

NBQX

NBQX (2,3-dioxo-6-nitro-7-sulfamoyl-benzoquinoxaline) is an antagonist of the AMPA receptor. Quinoxalinedione and NBQX are Lactams, Quinones and quinoxalines.

See Quinoxalinedione and NBQX

NMDA receptor

The N-methyl-D-aspartate receptor (also known as the NMDA receptor or NMDAR), is a glutamate receptor and predominantly Ca2+ ion channel found in neurons.

See Quinoxalinedione and NMDA receptor

O-Phenylenediamine

o-Phenylenediamine (OPD) is an organic compound with the formula C6H4(NH2)2.

See Quinoxalinedione and O-Phenylenediamine

Receptor antagonist

A receptor antagonist is a type of receptor ligand or drug that blocks or dampens a biological response by binding to and blocking a receptor rather than activating it like an agonist.

See Quinoxalinedione and Receptor antagonist

Selurampanel

Selurampanel (INN, code name BGG492) is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy.

See Quinoxalinedione and Selurampanel

Zonampanel

Zonampanel (INN, code name YM872) is a quinoxalinedione derivative drug and competitive antagonist of the AMPA receptor which was being investigated by Yamanouchi/Astellas Pharma as a neuroprotective drug for the treatment of ischemic stroke but never completed clinical trials. Quinoxalinedione and Zonampanel are quinoxalines.

See Quinoxalinedione and Zonampanel

See also

Quinones

• 2,6-Dibromoquinonechlorimide
• 2,6-Dichloroquinone-4-chloroimide
• Acenaphthoquinone
• Anthanthrone
• Anthraquinones
• Benzoquinones
• Chrozophoridin
• DNQX
• Dibromoanthanthrone
• Dithymoquinone
• Fagopyrin
• Haematopodin
• Hipposudoric acid
• Indolequinones
• Mitomycin C
• Mitomycins
• Mitosene
• NBQX
• Naphthoquinones
• Perzinfotel
• Phanquinone
• Phenanthrenequinone
• Pixantrone
• Porfiromycin
• Quinone
• Quinoxalinedione
• Terphenylquinones
• Thelephoric acid
• Torreyanic acid
• Xestoquinone

Quinoxalines

• 2,3-Bis(acetylmercaptomethyl)quinoxaline
• Becampanel
• Brimonidine
• CA77.1
• CGS-12066A
• CNQX
• CX-516
• Carbadox
• Caroverine
• DNQX
• Echinomycin
• Erdafitinib
• Fanapanel
• Glecaprevir
• Licostinel
• NBQX
• PEAQX
• Quinalphos
• Quinoxaline
• Quinoxalinedione
• SRT-1720
• Sulfaquinoxaline
• Sunobinop
• Varenicline
• Zonampanel

References

[1] https://en.wikipedia.org/wiki/Quinoxalinedione

Also known as Quinoxalinediones.